75 results about "Herpes simplex virus DNA" patented technology

The invention relates to the technical field related to immunological detection, in particular to a mouse anti-porcine herpesvirus type 1 gE monoclonal antibody as well as an immunogen and application of the mouse anti-porcine herpesvirus type 1 gE monoclonal antibody. The amino acid sequences of complementary determining regions CDR1, CDR2 and CDR3 of a heavy chain variable region of the monoclonal antibody or the antigen binding fragment of the monoclonal antibody are respectively as follows: GFSLSTSGMG, IVWGSETGRVTISRDNSK and VRYYDGDDD, and the amino acid sequences of complementary determining regions CDR1, CDR2 and CDR3 of a light chain variable region of the monoclonal antibody or the antigen binding fragment of the monoclonal antibody are respectively as follows: KSSQSLLYSDGKTFLN, LGSNRAS and SSLPHED. The monoclonal antibody can be specifically combined with gE proteins of all subtypes of the porcine herpesvirus type 1, and a porcine herpesvirus type 1 detection kit prepared from the monoclonal antibody has the advantages of high sensitivity, strong specificity, wide detection range, short detection time and the like.

The invention discloses a cat kidney suspension culture cell line suitable for serum-free suspension culture and application of the cat kidney suspension culture cell line. The name of the cell line is F81-B4, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.46350. After 50 generations of continuous subculture, the cells still can maintain the original proliferation level and cellular morphology, the cell number can reach 9.0 * 10 < 6 > / mL after the cells are subcultured at the density of 1.0 * 10 < 6 > / mL for three days, the multiplication time is 22-26 hours, and the cell proliferation speed is equivalent to that in a shake flask when the cells are amplified to a 10L bioreactor for culture. The cell line is highly susceptible to feline parvovirus, feline calicivirus, feline herpes virus, canine parvovirus and canine distemper virus, the virus content of a virus solution harvested 72 h after FPV virus inoculation can reach 107.5 TCID50 / mL, the virus content of a virus solution harvested 24 h after FCV virus inoculation can reach 1010.8 TCID50 / mL, the virus content of a virus solution harvested 48 h after FHV-1 virus inoculation can reach 107.5 TCID50 / mL, compared with an existing F81 adherent cell production process, the production process has the advantages that the production efficiency is high, and the production cost is low. The method has the characteristics of rapid lesion, short virus collection time and high titer. The cell matrix is an ideal cell matrix which can be used for culturing the three viruses.

The invention discloses a monoclonal antibody of feline herpesvirus gB protein, an antigen epitope peptide recognized by the monoclonal antibody and application of the monoclonal antibody. The monoclonal antibody of the feline herpesvirus gB protein comprises an antibody heavy chain and an antibody light chain, wherein a variable region of the antibody light chain comprises a CDR1 consisting of an amino acid sequence as shown in SEQ ID NO.1, a CDR2 of which the amino acid sequence is QVS and a CDR3 consisting of an amino acid sequence as shown in SEQ ID NO.3; a variable region of the antibody heavy chain comprises a CDR1 composed of an amino acid sequence shown in SEQ ID NO.4, a CDR2 composed of an amino acid sequence shown in SEQ ID NO.2 and a CDR3 composed of an amino acid sequence shown in SEQ ID NO.5. According to the research, one specific monoclonal antibody is successfully prepared and obtained, the antigen epitope recognized by the specific monoclonal antibody is identified, and a biological foundation is laid for developing a specific detection reagent of FHV-1.

The invention discloses a self-aggregation-induced emission type photosensitizer and a preparation method and application thereof. The photosensitizer has excellent AIE performance, and singlet oxygen can be efficiently generated after aggregation in a physiological environment; and the photosensitizer can effectively overcome the aggregation-induced quenching phenomenon, and has a synergistic effect with the lovir drugs, so that the anti-herpes virus activity is remarkably improved, and the dosage and side effects are reduced.

The present invention relates i.a. to a method for treating or preventing avian influenza virus infections in turkeys comprising administering an effective amount of a rHVT-H5HA COBRA.

A patch composition for targeting herpes virus comprising the following ingredients: a patch base, trisodium phosphate, malic acid, sorbitol, sodium benzoate, cellulose gum, peppermint, sodium saccharin, naringin, wind wheel grass extract, xanthan gum, polyethylene glycol-8, calcium carbonate, hydroxyethyl cellulose, hydroxypropyl guar gum, sodium nitrate, hydrated silica, sodium lauryl sulfate, strontium chloride hexahydrate, tranexamic acid, two-faced needle extract, sodium monofluorophosphate, sea salt, potassium nitrate, sodium chloride, and purified water q.s.

The invention discloses a visual detection reagent for koi herpesvirus. The visual detection reagent comprises a lower phase MIRA amplification system and an upper phase CRISPR / Cas12a detection system which are arranged in the same reaction tube. The method has no high professional requirement on detection personnel, is low in equipment requirement, short in detection time and high in sensitivity, has extremely high specificity and simplicity and is convenient to popularize and apply, and the final detection result can be directly observed by naked eyes.

The present application relates to an avian cell line capable of supporting viral growth of Marek's Disease Virus (MDV), including Herpes Virus of Turkeys (HVT), methods of producing such cell lines, and therapeutic uses of the cell lines and resulting vaccines.

Provided are use of a bioactive protein in the preparation of a drug for treating herpes virus infection and a pharmaceutical composition for treating herpes virus infection. The pharmaceutical composition mainly comprises a bioactive protein, a matrix, a humectant, a pH regulator, and a preservative. The present invention has the following technical effects: 1) By means of a large amount of research and experimental verification, the inventors have discovered for the first time that anhydridized lactoferrin, a modified bioactive protein, has an inhibitory effect on herpes zoster virus (VZV). 2) In the pharmaceutical composition, the type and amount of excipient and the proportion of the main ingredient are reasonable. The pharmaceutical composition is administered in ointment form, in spray form, or in other dosage forms suitable for external use, has a significant therapeutic effect, has small local toxic side effects, has very low acute dermal toxicity, causes no irritation or allergy, does not interfere with normal skin functions, and is safe and effective.

The present invention provides a new silicone gel composition suitable for preparing an anti-herpes viruses product of natural origin. The new composition is capable of permeating at the target epidermis side of the skin. The new composition is capable of retaining in the target epidermis side of the skin for a certain period. The present invention also relates to the topical use of the silicone gel composition for the treatment of viruses of the herpes family at a posology regime.

The invention discloses an application of a natural anthocyanin substance in preparation of an antiviral drug, which is characterized in that anthocyanin is used as a potential effective component for inhibiting the activity of herpes virus DNA polymerase, and the activity of the DNA polymerase is inhibited through the combination of the anthocyanin and the DNA polymerase, so that a good anti-herpes virus effect is realized.

The invention discloses a method for killing bovine herpesvirus by sodium chloride aerosol. The method comprises the following steps: (1) preparing sodium chloride aerosol of which the average particle size is 800nm and the particle size distribution is between 500nm and 8mu m, in the specific preparation process, respectively introducing a saturated sodium chloride aqueous solution and absolute ethyl alcohol into dry airflow of a spray dryer according to a volume ratio of 1: 1, and drying by the spray dryer to prepare the sodium chloride aerosol; and (2) the prepared sodium chloride aerosol is used as a bovine herpes virus killing agent to kill bovine herpes viruses, and in the virus killing process, the dosage is 10-60 mg, and the killing time is 10-30 s. The sodium chloride aerosol has the advantages that the sodium chloride aerosol has special antivirus efficacy in a specific dosage and time range, a high-concentration sodium chloride solution can dehydrate bacterial cells and destroy cell membrane structures of the bacterial cells through osmotic pressure difference to cause growth inhibition or death of bacteria, and especially 100% of bovine herpes viruses (BHV-1) can be killed in a very short time with a small dosage of sodium chloride aerosol.

The invention relates to a loop-mediated isothermal amplification method for rapid inspection and quarantine of horse herpes viruses 1 and 4 of imported racing horses. The loop-mediated isothermal amplification method comprises the following steps: S1, obtaining a biological sample of the imported racing horses; s2, extracting a nucleic acid template from the biological sample; s3, mixing the nucleic acid template with a reaction system containing nucleic acid polymerase and a specific loop-mediated isothermal amplification primer group aiming at the equine herpes virus type 1 or type 4; s4, performing a nucleic acid amplification reaction under a constant temperature condition; and S5, detecting an amplification product, and judging whether the imported racing horse is infected with the horse herpes virus type 1 or type 4 or not. The loop-mediated isothermal amplification method for rapid inspection and quarantine of the imported racing horse herpes viruses type 1 and type 4 can effectively meet the requirements of rapid customs clearance and epidemic disease prevention and control of imported racing horses.

The invention relates to a novel thiazole compound as shown in a formula I and pharmaceutically acceptable salts thereof, or solvates or hydrates thereof, and also relates to a pharmaceutical composition containing the compound, a method for preparing the compound, and application of the compound in preparation of medicines for preventing and / or treating diseases caused by herpes viruses.

The invention relates to the technical field of biological viruses, and particularly discloses an efficient cat herpesvirus purification process which comprises the following steps: 1) clarifying virus harvesting liquid; and 2) concentrating, washing and filtering the clarified liquid by using a hollow fiber column. And the virus content of the final sample is not obviously lost, the total protein can be reduced to be less than 80 mu g / ml, and the turbidity is as low as 20.3 NTU. As the cat herpes virus has the characteristics of temperature sensitivity, poor shear force tolerance, similar virions and impure proteins in size, incapability of removing impure proteins through a filtering method and the like, a great challenge is brought to a downstream purification process, and the method provides an efficient cat herpes disease purification process; the method greatly reduces the antigen loss, has the characteristics of low production cost, excellent purification effect and the like, avoids the use of multi-step purification steps such as a chromatographic process, and enables the purification process to be simpler and more efficient.

Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.

Disclosed herein include methods and compositions for pig-to-human organ xenotransplantation using genetically modified pigs with triple-gene knockouts and human gene insertions. In some embodiments, the organ xenotransplantation is a pig-to-human kidney xenotransplantation demonstrating the restoration of renal function. Also disclosed are methods and compositions for preventing acute rejection and / or reactivation of porcine herpesvirus, which contributes to advancing xenotransplantation as a viable solution to the global organ shortage.

The present disclosure provides nanostructures and nanostructure-based vaccines. Some nanostructures of the present disclosure display antigens capable of eliciting an immune response to infectious agents such as bacteria, viruses, and pathogens. Some vaccines of the present disclosure are useful for preventing or reducing the severity of infection by infectious agents including, but not limited to, Lyme disease, pertussis, herpes virus, orthomyxovirus, paramyxovirus, pneumovirus, filovirus, flavivirus, reovirus, retrovirus, meningococcus, or malaria. The antigens can be attached to the core of the nanostructure non-covalently or covalently, including as a fusion protein or by other means disclosed herein. Multimeric antigens can optionally be displayed along the symmetry axis of the nanostructure. Also provided are proteins and nucleic acid molecules encoding such proteins, vaccine compositions, and methods of administration.

The invention discloses a CTL epitope polypeptide of bovine herpesvirus and application thereof, and belongs to the technical field of polypeptide vaccine preparation. The CTL epitope polypeptide of the bovine herpesvirus disclosed by the invention is a polypeptide with an amino acid sequence of SEQ ID No. 1 or SEQ ID No. 2. The BoHV-1 specific CTL epitope polypeptide can be stably combined with BoLA-I molecules, has the potential of activating CD8 + T cells to generate immune response and inducing an organism to generate specific CTL reaction, can be used as a vaccine component to be applied to preventive immunity of BoHV-1, can be used for preparing BoHV-1 specific antigen epitope vaccines or polypeptide vaccines, and can be applied to preparation of the BoHV-1 specific antigen epitope vaccines or polypeptide vaccines. The monoclonal antibody has the advantages of high specificity, good safety, strong immunogenicity and the like, and has remarkable application potential and popularization value in immune prevention and control of infectious bovine rhinotracheitis (IBR).

The application relates to methods and intermediates for synthesizing the thiazole derivative Coumpound (1) useful in treating and / or inhibiting the development or progression of diseases or disorders caused by, or associated with, herpes virus infection.

A herpes virus vector is provided with both transcriptional and translational control. Within various embodiments the herpes virus vector is based upon a modified herpes virus and has both ICP27 and ICP34.5 under control of a CEA promoter and miRNA-124 / 143, respectively, and deletion of at least one copy of terminal repeat long region is provided to increase safety without sacrificing efficacy. The herpes virus vector can also incorporate a virus-expressed cytokine cassette encoding IL-12, IL-15 / IL-15RA under the control of CXCR4 promoter.

The invention discloses a recombinant protein as well as a coding gene and application thereof, and belongs to the technical field of bioengineering. The invention designs a recombinant protein which is composed of two subunits with different functions, and design and transformation are carried out on the basis of a conserved sequence of an alpha herpes virus protein with an immune escape function, so that the secretory expression of the recombinant protein is promoted, and the defects of inclusion body formation, overhigh host toxicity and high target protein purification difficulty are overcome. Experimental results show that the recombinant protein provided by the invention has a remarkable effect of inhibiting innate immunity of cells, and can effectively inhibit interferon generated by innate immunity of cells, so that the titer of cultured viruses is improved.

The invention discloses a cat herpesvirus circular RNA vaccine and application thereof. According to the circular RNA vaccine, four glycoproteins gB, gD, gE and gI of feline herpes virus type 1 (FHV-1) are subjected to systematic antigen optimization, and a fusion protein is constructed on the basis, so that synergistic immunization of multiple antigens is realized; furthermore, the circular RNA vaccine is prepared on the basis of the optimized antigens and fusion proteins. Compared with the prior art, the application realizes the development and production of the cat virus vaccine which is safer, more stable and more lasting in immune effect, the process is stable and reliable, and the large-scale production of high-quality vaccine products can be realized.

The application belongs to the technical field of biology, and particularly relates to a hybridoma cell strain secreting a monoclonal antibody against gE protein of swine herpes virus 1 (SuHV-1), the monoclonal antibody and application thereof. The hybridoma cell strain secreting the monoclonal antibody against gE protein of swine herpes virus 1 (SuHV-1) is characterized in that the hybridoma cell strain is preserved in the China General Microbiological Culture Collection Center, and the preservation number is CGMCC No. 46719. The application utilizes the monoclonal antibody secreted by the hybridoma cell strain secreting the monoclonal antibody against gE protein of swine herpes virus 1 (SuHV-1), and provides a full-automatic magnetic microparticle chemiluminescence detection kit, solves the problems existing in the prior art, and realizes full-automatic rapid detection of pseudorabies virus gE antibodies.

The present application relates to the technical field of virus detection, in particular to a primer probe combination for identifying mixed infection pathogens of cattle and application and kit thereof. When identifying cattle pathogens, the nucleotide sequence of the upstream primer of the primer probe combination used is shown in SEQ ID No. 1, the nucleotide sequence of the downstream primer is shown in SEQ ID No. 2, the nucleotide sequence of the probe is shown in SEQ ID No. 3, and the like scheme. The present application can detect and identify bovine epidemic fever virus, bovine herpes virus 4, bovine rotavirus and clostridium welchii through four groups of primer probes. The primer probe combination provided by the present application can identify and diagnose four common pathogens of cattle through a one-tube reaction system by fluorescence quantitative PCR method, and can also identify mixed infection samples, has the advantages of accurate identification, high sensitivity, simple operation, short time consumption and the like, and can provide effective technical means for the diagnosis of cattle infectious disease pathogens and disease prevention in China.

The invention relates to the technical field of biological detection, and discloses a primer probe group and a detection kit for simultaneously detecting three porcine pathogens. The invention firstly provides two primer probe groups for simultaneously detecting the porcine pseudorabies virus, the porcine cytomegalovirus and the porcine lymphotropic herpesvirus, one group is used for detecting the porcine lymphotropic herpesvirus type 1 and the porcine lymphotropic herpesvirus type 2, the other group is used for detecting the porcine lymphotropic herpesvirus type 2, and the other group is used for detecting the porcine lymphotropic herpesvirus type 3. And the other group of primers is used for detecting the swine lymphotropic herpesvirus type 3. Meanwhile, the invention also provides a detection kit containing the primer probe group. When being used for detection, the primer probe group has the advantages of high sensitivity, high specificity and simplicity in operation, can be used for simultaneously, quickly and accurately detecting the porcine pseudorabies virus, the porcine cytomegalovirus and the porcine lymphotropic herpesvirus type 1, the porcine cytomegalovirus type 2 and the porcine lymphotropic herpesvirus type 3, and provides an effective technical means for detecting and distinguishing the three viruses and subtypes in a laboratory.

The invention belongs to the technical field of medicines, and particularly relates to application of Arylquin 1 in preparation of antiviral drugs. It is found and verified for the first time that Arylquin 1 can effectively inhibit replication of various viruses including vesicular stomatitis virus, bovine ephemeral fever virus and bovine herpes virus type I, toxicity to cells is relatively small, it is indicated that Arylquin 1 has the prospect of being developed into broad-spectrum antiviral drugs, new drug application is developed for Arylquin 1, and the Arylquin 1 has good application prospects. An experimental foundation is also laid for developing efficient and specific antiviral drugs, and good application value is achieved.

The present invention is directed to chimeric antigen receptor (CAR) compositions and methods of their use in cancer and anti-viral immunotherapy. In particular, the CAR of the invention comprises a costimulatory signal (CSS) domain comprising herpes virus entry mediator protein (HVEM) or a functional fragment or variant thereof. CARs comprising such a HVEM CSS exhibit enhanced effector function.

The invention belongs to the technical field of biotechnology and genetic engineering, and relates to recombinant XAF1 and application of an inherent disorder region of the recombinant XAF1 in preparation of a medicine for preventing and treating herpes virus infection diseases. The XAF1 or the IDR fragment thereof provided by the invention can be combined with an STING RNA transcript and can promote the synthesis of endogenous STING. The invention also finds that XAF1 or an IDR fragment thereof can inhibit HSV-1 replication in vivo and in vitro, and alleviate nerve injury of herpes simplex encephalitis and pneumonia injury.

The invention discloses a gB, gH / gL and K8.1 multi-epitope DNA (deoxyribonucleic acid) vaccine for preventing KSHV (Kaposi's sarcoma associated herpes virus), and relates to the technical field of vaccines, in particular to a gB, gH / gL and K8.1 multi-epitope DNA vaccine for preventing KSHV infection, which is delivered by adopting a nano-carrier beta-CD-PEI, and simultaneously delivers a sulfo-modified small-fragment nucleic acid adjuvant, so that the KSHV infection can be effectively prevented and treated. The multi-epitope DNA vaccine mainly comprises four plasmids with His tags, the four plasmids are pcDNA3.1 (+)-gB-his, pcDNA3.1 (+)-K8.1-his, pcDNA3.1 (+)-gH-his and pcDNA3.1 (+)-gL-his, the four plasmids are combined on beta-CD-PEI through electrostatic adsorption, an adjuvant CPGodn1826 is adsorbed, and the KSHV nano multi-epitope DNA vaccine which is stable, high in delivery efficiency and good in immunogenicity is formed. The invention further provides a construction method of the DNA nano vaccine, the nano vaccine is characterized, and the immune effect is verified in a mouse body. Compared with a traditional vaccine, the vaccine provided by the invention has good immunogenicity and safety, and has a relatively great application prospect.